n-formyl-13-dihydrocarminomycin has been researched along with Metabolic Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anaya, BJ; Ballesteros, MP; Cerda, JR; D'Atri, RM; Kara, A; Luciano, FC; Ruiz, HK; Serrano, DR; Yuste, I | 1 |
1 other study(ies) available for n-formyl-13-dihydrocarminomycin and Metabolic Syndrome
| Article | Year |
|---|---|
Engineering of 3D printed personalized polypills for the treatment of the metabolic syndrome.
Topics: Diabetes Mellitus, Type 2; Drug Liberation; Humans; Metabolic Syndrome; Printing, Three-Dimensional; Solubility; Tablets; Technology, Pharmaceutical | 2023 |